WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Tirzepatide

Governed registry record

25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

  1. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.

    Walter Masson, Martín Lobo, Juan P Nogueira, Leandro Barbagelata, Pedro Touzas, Juan P Frías · 2026

    DOI: 10.1007/s11154-025-09991-4PMID: 41032183

  2. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).

    Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó Hartaigh, Signe Stensen, Kerem Ozer · 2026

    DOI: 10.1111/dom.70436PMID: 41491349

  3. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.

    Michelle Look, Julia P Dunn, Robert F Kushner, Dachuang Cao, Charles Harris, Theresa Hunter Gibble, Adam Stefanski, Ryan Griffin · 2025

    DOI: 10.1111/dom.16275PMID: 39996356

  4. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

    Stephen J Nicholls, Imre Pavo, Deepak L Bhatt, John B Buse, Stefano Del Prato, Steven E Kahn, A Michael Lincoff, Darren K McGuire · 2025

    DOI: 10.1056/NEJMoa2505928PMID: 41406444

  5. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Tamara S Hannon, Lily C Chao, Margarita Barrientos-Pérez, Karthik Chandrasekhar Pamidipati, Laura Fernández Landó, Clare J Lee, Hiren Patel, Brandon K Bergman · 2025

    DOI: 10.1016/S0140-6736(25)01774-XPMID: 40975112

  6. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

    Louis J Aronne, Deborah Bade Horn, Carel W le Roux, Wayne Ho, Beverly L Falcon, Elisa Gomez Valderas, Sagar Das, Clare J Lee · 2025

    DOI: 10.1056/NEJMoa2416394PMID: 40353578

  7. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

    2025

    DOI: 10.1056/NEJMoa2410027PMID: 39555826

  8. Tirzepatide for Obesity Treatment and Diabetes Prevention.

    Ania M Jastreboff, Carel W le Roux, Adam Stefanski, Louis J Aronne, Bruno Halpern, Sean Wharton, John P H Wilding, Leigh Perreault · 2025

    DOI: 10.1056/NEJMoa2410819PMID: 39536238

  9. Tirzepatide for overweight and obesity management.

    Malak Hamza, Dimitris Papamargaritis, Melanie J Davies · 2025

    DOI: 10.1080/14656566.2024.2436595PMID: 39632534

  10. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    2024

    DOI: 10.1001/jama.2023.24945PMID: 38078870

  11. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

    Patricia J Rodriguez, Brianna M Goodwin Cartwright, Samuel Gratzl, Rajdeep Brar, Charlotte Baker, Ty J Gluckman, Nicholas L Stucky · 2024

    DOI: 10.1001/jamainternmed.2024.2525PMID: 38976257

  12. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis

    2024

    DOI: 10.1056/NEJMoa2401943PMID: 38856224

  13. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

    Lin Zhao, Zhifeng Cheng, Yibing Lu, Ming Liu, Hong Chen, Min Zhang, Rui Wang, Yuan Yuan · 2024

    DOI: 10.1001/jama.2024.9217PMID: 38819983

  14. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

    2024

    DOI: 10.1056/NEJMoa2404881PMID: 38912654

  15. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.

    Qingyue Zeng, Jiao Xu, Xingyu Mu, Yi Shi, Hong Fan, Shuangqing Li · 2023

    DOI: 10.3389/fendo.2023.1214334PMID: 37908750

  16. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

    2023

    DOI: 10.1038/s41591-023-02597-wPMID: 37845521

  17. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)

    2023

    DOI: 10.1016/S0140-6736(23)01200-XPMID: 37385275

  18. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

    Dominik Dahl, Yukiko Onishi, Paul Norwood, Ruth Huh, Ross Bray, Hiren Patel, Ángel Rodríguez · 2022

    DOI: 10.1001/jama.2022.0078PMID: 35133415

  19. Tirzepatide Once Weekly for the Treatment of Obesity

    2022

    DOI: 10.1056/NEJMoa2206038PMID: 35658024

  20. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.

    Naveed Sattar, Darren K McGuire, Imre Pavo, Govinda J Weerakkody, Hiroshi Nishiyama, Russell J Wiese, Sophia Zoungas · 2022

    DOI: 10.1038/s41591-022-01707-4PMID: 35210595

  21. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

    Michael A Nauck, David A D'Alessio · 2022

    DOI: 10.1186/s12933-022-01604-7PMID: 36050763

  22. Tirzepatide: A Systematic Update.

    Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, Stanislovas S Jankauskas, Pasquale Mone, Gaetano Santulli · 2022

    DOI: 10.3390/ijms232314631PMID: 36498958

  23. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)

    2021

    DOI: 10.1016/S0140-6736(21)01324-6PMID: 34186022

  24. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

    2021

    DOI: 10.1056/NEJMoa2107519PMID: 34170647

  25. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4)

    2021

    DOI: 10.1016/S0140-6736(21)02188-7PMID: 34672967